

Vitamin K

Classification

Fat-soluble vitamin

Indications

■ CCP: Major, life-threatening bleeding in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency

Contraindications

Hypersensitivity to vitamin K (phytonadione) or any component of the formulation

Adult dosages

■ CCP: Major, life-threatening bleeding in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency

- 10 mg IV/IO, **no faster than 1 mg/minute**.
- Do not repeat dose.

Pediatric Considerations And Dosing

■ CCP: Major, life-threatening bleeding in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency

- Significant bleeding: 0.5-2 mg IV. Do not repeat.
- Life-threatening bleeding: 5 mg IV. Do not repeat.

Mechanism Of Action

Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown.

Pharmacokinetics

- Onset: 1-2 hours
- Peak: 12-14 hours
- Metabolism: hepatic
- Excretion: urine and feces

Adverse Effects

Cardiovascular: Chest pain, flushing, hypotension, tachycardia, weak pulse

Central nervous system: Dizziness

Dermatologic: Diaphoresis, eczematous rash, erythema, erythematous rash, pruritic plaques of the skin, urticaria

Gastrointestinal: Dysgeusia

Hepatic: Hyperbilirubinemia

Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction

Local: Injection site reaction (including pain, swelling, tenderness)

Respiratory: Cyanosis, dyspnea

Miscellaneous: Lesion (scleroderma-like)

Warning And Precautions

Fatal hypersensitivity reactions, including anaphylaxis, have occurred with parenteral use; onset may occur during or immediately after intravenous (IV) or intramuscular (IM) administration. Reactions have occurred despite dilution to avoid rapid IV infusion and with the first dose.

